China approves first biosimilar, Shanghai Henlius’ HLX01

China's National Medical Products Administration (NMPA) approved the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China).

The chimeric mAb against CD20 was approved

Read the full 276 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE